Randomized phase II study of dual epidermal growth factor receptor inhibition with erlotinib and panitumumab with or without irinotecan as second-line therapy in patients with metastatic colorectal cancer

被引：1

作者：

Kalyan, Aparna

Kircher, Sheetal Mehta

Nimeiri, Halla Sayed

Wisinski, Kari Braun

Suh, Jason J.

Jones, Michael

Lakhani, Ali R.

Rademaker, Alfred

Mulcahy, Mary Frances

Benson, Al Bowen

机构：

[1] Northwestern Med Dev Therapeut, Chicago, IL USA

[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[3] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA

[4] Joliet Onc Hem Assoc, Joliet, IL USA

[5] Jones Clin, Germantown, TN USA

[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[7] Northwestern Univ, Chicago, IL 60611 USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.e15037

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e15037

引用

页数：2